Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...